MOH — authorised 9 September 2022
- Marketing authorisation holder: BRISTOL-MYERS SQUIBB
- Status: likely_approved
MOH authorised Sotyktu on 9 September 2022
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 9 September 2022.
BRISTOL-MYERS SQUIBB holds the Israeli marketing authorisation.